Search | Page 12 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation (AML)

    ... Cohort 1 will enroll up to 26 patients with relapsed or refractory AML and confirmed FLT3 mutation without prior exposure to a FLT3 ... Cohort 2 will enroll up to 12 patients with relapsed or refractory AML and confirmed FLT3 mutation with prior exposure to a FLT3 ...

    Clinical Trial last updated 05/09/2016 - 4:09pm.

  2. Historical perspectives on myelodysplastic syndromes

    ... etiology and nature of disorders described as " refractory anemia ", "preleukemia", and with other terminology ...

    Research Article last updated 10/02/2012 - 9:52am.

  3. A Meta-Analysis of the Relationship between Cigarette Smoking and Incidence of Myelodysplastic Syndromes.

    ... the United States, or in Europe, female in gender, had refractory anemia (RA)/RA with ringed sideroblasts (RARS) or RA ...

    Research Article last updated 07/09/2013 - 3:26pm.

  4. Aplastic anemia: therapeutic updates in immunosuppression and transplantation

    ... eltrombopag, is showing promising activity in refractory cases. The most recent advances in HSCT and IST in SAA are ...

    Research Article last updated 01/02/2013 - 2:25pm.

  5. Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS (AML)

    ... intermediate-dose cytarabine in subjects with relapsed/ refractory AML or MDS. Phase 2 will investigate overall response rate ... agent (Arm A) and 2) subjects with relapsed and refractory AML after treatment failure of up to 1 prior chemotherapy ...

    Clinical Trial last updated 05/02/2016 - 11:06am.

  6. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... and iron chelation. Management of progressive or refractory disease: There are no approved interventions for patients with progressive or refractory disease particularly after hypomethylating based therapy. Options ...

    Research Article last updated 02/04/2014 - 1:37pm.

  7. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... and iron chelation. MANAGEMENT OF PROGRESSIVE OR REFRACTORY DISEASE: At the present time, there are no approved interventions for patients with progressive or refractory disease particularly after hypomethylating based therapy. Options ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... and iron chelation. Management of progressive or refractory disease: At the present time there are no approved interventions for patients with progressive or refractory disease particularly after hypomethylating based therapy. Options ...

    Research Article last updated 07/31/2012 - 2:02pm.

  9. Myelodysplastic syndromes.

    ... are classified as having 1 of 5 subtypes of disease: refractory anemia (RA); RA with ringed sideroblasts (RARS); RA ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children

    ... Acute lymphocytic leukemia in relapse or primary refractory disease with a circulating blast count of no more than 10,000/mm^3 Acute myeloid leukemia in relapse or primary refractory disease with a circulating blast count of no more than 10,000/mm^3 ...

    Clinical Trial last updated 06/13/2016 - 2:29pm.